Delivery Order SPE2DB25D3109-SPE2DB26FP4PR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Enbrel 50 mg/ml syringes, with a contract ceiling value of $9,651.82. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the vendor's...
- The Defense Logistics Agency awarded a $17,257.88 delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Enbrel 50 mg/ml syringes. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a $10,359.88 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of September 16, 2025. The contract was competitively awarded with no set-aside designation and is structured as a firm fixed-price delivery order. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for ENBREL 50 mg/ml syringes valued at $29,284.84. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order will be fulfilled at the contractor's Conshohocken, Pennsylvania facility with...
- The Defense Logistics Agency awarded a $14.5K delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of ENBREL 25 mg/0.5 ml syringes. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $13,737.99 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL syringes, with an ultimate completion date of September 12, 2025. This contract represents a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and operates as a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $18,364.76 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/ml syringes. This firm fixed price contract, awarded on June 17, 2025, with an ultimate completion date of June 18, 2025, represents a competitively awarded non-set-aside procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Enbrel 50 mg/ml syringes, with a ceiling value of $21,290.98. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 22, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery order issued under a larger indefinite delivery contract vehicle,...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of ENBREL 50 mg/mL SureClick auto-injectors, valued at $75,184.20. This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation...
- The Defense Logistics Agency awarded a $31,043.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of September 5, 2025. This non-set-aside award was made competitively and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion vehicle running through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB26FP4PRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML syringes valued at $13,737.99 on November 3, 2025, with completion scheduled for November 4, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract carries no set-aside designation, reflecting AmerisourceBergen's proven capability to compete and perform within the federal pharmaceutical procurement marketplace. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. The company's comprehensive pharmaceutical supply portfolio includes specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This award for ENBREL—a immunosuppressant biologic used in treating conditions such as rheumatoid arthritis and other autoimmune diseases—demonstrates the company's ongoing role in supporting Defense Health Agency requirements and broader military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.7k | 11/3/25 |